AstraZeneca is working in collaboration with the molecular diagnostics firm Myriad Genetics’ for its tes...Read more
Japan's Otsuka Pharmaceutical recently announced that it has acquired US-based Visterra for approx...Read more
Carragelose®, a broadly effective compound for treating cold viruses, can be combined with Xylometazoline,...Read more
NICO Corporation, Neurosurgical medical device maker issued patent for additional protection around its unique...Read more
Europe’s largest privately held biotech company, Germany-based BioNTech, has raised $270 million to supp...Read more
ASEAN – Emerging hotspot for Big pharmas
ASEAN is growing, and growing with it is the region’s pharma sector. With growth in developed markets flattening, pharma industry is betting on lucrative ASEAN markets for profits. Think of Asia’s emerging markets and the instant names that appear are India and China. Undoubtedly, these are huge markets for the industry. But apart from these main markets, ASEAN’s emerging markets, with an annual growth rate of 11 per cent and huge untapped potential, provide a massive opportunity for big pharma to expand and grow in this region.